摘要
HER2阳性乳腺癌的特点是转移患者存活率低。耐药性和疾病复发的发展是与目前可用的HER2阳性乳腺癌治疗相关的主要问题。有两种主要的针对HER2阳性乳腺癌的治疗方法,单克隆抗体和酪氨酸激酶抑制剂,这两种疗法都有其优点和局限性。为了解决与现有疗法相关的限制,使用抗体和TKI作为组合疗法证明是更有效的。可以对酪氨酸激酶抑制剂进行各种化学修饰以开发具有增加的对HER2激酶选择性的新配体。许多酪氨酸激酶抑制剂处于治疗HER2阳性乳腺癌的临床试验的不同阶段。在当前的综述文章中,已经报道了各种HER2酪氨酸激酶抑制剂的最新进展。各种结构不同的支架与HER2受体结合并显示有效的抗癌活性。对支架的结构和药效要求进行了详细讨论,以发现治疗HER2阳性乳腺癌的有效候选药物
关键词: 乳腺癌,HER1 / HER2,酪氨酸激酶抑制剂,耐药性,单克隆抗体,曲妥珠单抗。
图形摘要
Current Cancer Drug Targets
Title:Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer
Volume: 18 Issue: 4
关键词: 乳腺癌,HER1 / HER2,酪氨酸激酶抑制剂,耐药性,单克隆抗体,曲妥珠单抗。
摘要: HER2 positive breast cancer is characterized by the low survival rate in the metastatic patients. Development of resistance and disease-relapse are the major problems associated with the currently available therapies for HER2 positive breast cancer. There are two major targeted therapies for HER2 positive breast cancer viz. monoclonal antibodies and tyrosine-kinase inhibitors, and both of these therapies have their advantages and limitations. To address the limitations associated with the existing therapies, use of antibodies and TKIs as combination therapy proved to be more effective. Various chemical modifications can be performed on tyrosine-kinase inhibitors to develop novel ligands with increased selectivity for HER2 kinase. A number of tyrosine-kinase inhibitors are in various phases of clinical trials for the treatment of HER2 positive breast cancer. In the current review article, recent developments on various HER2 tyrosine-kinase inhibitors have been reported. Various structurally different scaffolds bind to the HER2 receptor and exhibit potent anti-cancer activities. The structural and pharmacophoric requirements of the scaffolds are discussed in detail so as to discover effective drug candidates for the treatment of HER2 positive breast cancer.
Export Options
About this article
Cite this article as:
Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer, Current Cancer Drug Targets 2018; 18 (4) . https://dx.doi.org/10.2174/1568009617666170623122213
DOI https://dx.doi.org/10.2174/1568009617666170623122213 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Quality Survival with Fertility after Gynaecological and other Cancers
Current Women`s Health Reviews Lemon Juice as a Biocatalyst Under Ultrasound Irradiation: Synthesis and Pharmacological Evaluation of 2-amino 1,3,4-thiadiazoles
Anti-Cancer Agents in Medicinal Chemistry Receptor Tryosine Kinase Inhibitors as Potent Weapons in War Against Cancers
Current Pharmaceutical Design Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Novel Kynurenic Acid Analogues in the Treatment of Migraine and Neurodegenerative Disorders: Preclinical Studies and Pharmaceutical Design
Current Pharmaceutical Design Protein Arrays: Recent Achievements and their Application to Study the Human Proteome
Current Proteomics Hypoxia: Targeting the Tumour
Anti-Cancer Agents in Medicinal Chemistry The Endothelial-Mesenchymal Transition (EndMT) and Tissue Regeneration
Current Stem Cell Research & Therapy Effects of Endocrine Disruptors on Developmental and Reproductive Functions
Current Drug Targets - Immune, Endocrine & Metabolic Disorders MicroRNA Therapeutics in Neurological Disease
Current Pharmaceutical Design Regulatory T Cells and Skin Tumors
Recent Patents on Inflammation & Allergy Drug Discovery Plant Glycosides and Aglycones Displaying Antiproliferative and Antitumour Activities – A Review
Current Bioactive Compounds 1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry Nitric Oxide-Derived Oxidants with a Focus on Peroxynitrite: Molecular Targets,Cellular Responses and Therapeutic Implications
Current Pharmaceutical Design Drug Resistance: Challenges to Effective Therapy
Current Cancer Drug Targets Management of Chemotherapy Induced Cardiomyopathy
Current Cardiology Reviews Non Steroidal Anti-Inflammatory Drug Induced Damage on Lower Gastro-Intestinal Tract: Is There an Involvement of Microbiota?
Current Drug Safety From the Sea to Anticancer Therapy
Current Medicinal Chemistry Pathophysiology of NASH: Perspectives for a Targeted Treatment
Current Pharmaceutical Design